A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: Treatment of physician's choice;   Drug: vinorelbine Sponsors:   Sun Yat-sen University;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials